• Transcend Therapeutics

  Led · Series A · Feb 2023

  Transcend Therapeutics is a New York–based biotechnology company founded in 2021 and incubated by AlleyCorp that develops next-generation psychoactive drugs for neuropsychiatric diseases. Its lead compound, methylone (TSND-201), is described as short-acting with mild psychological effects and may require less clinician time than other psychedelic compounds. The company positions TSND-201 as a potential adjunctive treatment to existing pharmacotherapies (for example, SSRIs) to better integrate into current psychiatric care. Transcend already has real-world data for TSND-201 demonstrating responses in patients with PTSD. The company plans to use new funding to launch multiple clinical trials, including a phase II study. Leadership includes founders and senior executives with clinical and drug-development track records, including co-founders Blake Mandell and Ben Kelmendi, and senior development and clinical leads Martin Stogniew and Amanda Jones.

• Homecoming

  Led · Seed · Apr 2022

  Homecoming is a Toronto-based health-tech startup that offers a comprehensive patient care platform designed specifically for psychedelic therapy. The software supports clients before, between, and after psychedelic sessions with personalized guides, tasks, and daily check-ins. Clinics and retreats use the system to streamline operations, manage the entire patient experience, and reach more patients through modern therapy tools and precision data. By integrating preparation and integration support into one interface, the platform aims to improve clinical outcomes and operational efficiency. The company plans to use newly secured capital to scale its products and services, deepening its partnerships with psychedelic clinics and retreats. Although detailed user or revenue figures were not disclosed, management emphasizes its data-driven approach to enhancing patient engagement and care continuity.

• Beckley Psytech

  Led · Series B · Aug 2021

  Beckley Psytech is a British privately-held psychedelic drug developer focused on short-duration psychedelic therapies. Its two primary clinical programs are intranasal 5‑MeO‑DMT (BPL‑003), in a Phase IIb study targeting 225 moderate-to-severe TRD patients with a readout expected in H2 2024, and intravenous psilocin (ELE‑101), in a Phase I/IIa study with topline results expected in H1 2024. The company positions these shorter-duration candidates as potentially more scalable and efficient than longer-acting psychedelic-assisted therapies, which could improve patient access. Beckley and its partners are exploring digital patient-support tools and planning for future commercialization as part of development efforts. Financially, Beckley received a $50M strategic investment from atai—$40M primary and $10M secondary—which granted atai a 35.47% stake and board representation. The company previously raised an $80M Series B (upsized from $50M) in summer 2021. Beckley Psytech is a clinical-stage, privately held company developing a broad pipeline of psychedelic compounds to address neurological and psychiatric disorders. Its near-term clinical programs include a Phase 1b low-dose psilocybin trial in patients with SUNHA and a planned Phase 1 dose-ranging study of an intranasal 5-MeO-DMT formulation ahead of a Phase 2 trial in treatment-resistant depression. The company plans to expand its pipeline with new, unique and proprietary psychedelic compounds. Beckley Psytech leverages expertise developed over more than 20 years by the Beckley Foundation and was founded in 2019. It is based in Oxford, United Kingdom and states a vision for integrating clinically validated psychedelic medicines into modern medical practice. The company recently completed an oversubscribed Series B financing of $80 million to accelerate its clinical development programs. Beckley Psytech is a UK psychedelic medicine company and spin-out of the Beckley Foundation focused on turning psychedelic compounds into licensed pharmaceuticals. Its immediate focus is the development of 5-MeO-DMT as a treatment for neuropsychiatric diseases and the company is preparing to begin a Phase 1 clinical trial. The team also plans to explore other psychedelic agents targeting orphan diseases. The company was founded last year by Lady Amanda Feilding and CEO Cosmo Feilding Mellen and maintains a Scientific Advisory Board including Dr. Robin Carhart-Harris, Prof. Matthew Johnson and Prof. Guy Goodwin. Financially, the company has recently completed follow-on fundraising to push its drug development pipeline toward clinical trials.

• TRIPP

  Participated · Series A · Jun 2021

  TRIPP builds wellness-centered extended-reality experiences designed to deepen connection to self and support mental well-being. Its product spans AR smartglasses, VR headsets and smartphone apps and includes breathing exercises, binaural audio, guided visualizations, customizable worldscapes and a Composer feature for user-created content. TRIPP has acquired EvolVR (a VR meditation community), Eden (a cross-service world-building platform) and PsyAssist (acquired in 2021 to support psychedelic-assisted therapy clinics). The Eden acquisition is intended to let users further customize experiences, explore artworks and soundscapes, and connect with others globally. Founder Nanea Reeves, a former video-game industry executive, has assembled a team with gaming and immersive-technology expertise to broaden the company’s reach and creator engagement. Financially, TRIPP raised an $11.2M Series A extension to fund the Eden acquisition; the company says it now has more runway, is not cutting costs and is still hiring, though more cautiously than originally planned. Tripp creates immersive VR relaxation and guided meditation experiences that blend mindfulness structures with video-game mechanics and psychedelic-style visuals and audio without drugs. The company offers apps on Oculus and PlayStation VR and a subscription service priced at $4.99 per month. Users can follow guided sessions or build custom visual flows using the Tripp composer. Tripp says users have completed over 2 million sessions to date and claims short sessions can alleviate stress in as little as eight minutes. The startup is exploring enterprise in-office wellness solutions and is currently conducting clinical trials to study the platform’s therapeutic effectiveness. The pandemic has helped drive consumer and investor interest in mindfulness and mental-health focused products, according to CEO Nanea Reeves. Tripp is developing a native VR experience designed to change users' moods and mental states using a mix of audio, visual elements, gameplay mechanics, and meditation. The product is procedural and computer-generated and the company plans to tap a neural network to personalize and improve targeted "trips" for each user. Tripp frames the experience as a mindfulness journey aimed at producing flow states, calming or energizing users, and plans to expand to relevant mixed-reality platforms. The team is early in development and does not yet have a public demo; it is working with an outside studio on the experience. The startup has about half a dozen employees and is targeting a team of roughly ten people in the coming months. Tripp is based in Los Angeles and San Francisco and is led by CEO Nanea Reeves, cofounder Zachary "Zack" Norman, and CTO Andreja Djokovic. Financially, the company raised $4 million in a round led by Mayfield Fund.

No current team members are available.